Press Release
26
2023.07
Acceptance Of Clinical Trial Application For The Recbio’s Novel Adjuvanted Recombinant Shingles Vaccine REC610 In China And Overseas Clinical Trial Progress
20
2023.03
Two-Component Recombinant COVID-19 Vaccine ReCOV Granted With Emergency Use Authorization In Mongolia
13
2023.02
Completion Of The First Batch Of Subject Enrollmentfor The Phase I Clinical Trial Of The Company’s Novel Adjuvanted Recombinant Shingles Vaccine REC610
Publications